Pricing and reimbursement delays continue to impact biopharma revenue streams

Delays in obtaining pricing and reimbursement (P&R) have been identified as key hurdles holding back the pharmaceutical industry, according to market analysis. This trend is highlighted through responses to a survey taken from GlobalData’s State of the Biopharmaceutical Industry report, which reveals that industry professionals rate the impact of P&R processes among the top five leading factors currently impacting the sector. GlobalData is the parent company of Pharmaceutical Technology. In the survey, ...